OpenAlex
PricingAboutJobs
Log inGet started
Work

Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

HTML

Year: 2021
Type: conference-abstract
Source: Blood
DOI: 10.1182/blood-2021-145640
Authors: Frederick Lansigan, David Jacob Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason Melear, Suzanne Fanning, Kathryn S. Kolibaba, Christopher M. Reynolds, Grzegorz S. Nowakowski, Mecide Gharibo, Jung Ryun Ahn, Ju Li, Mathias J. Rummel, Jeff P. Sharman
Institutions: Dartmouth–Hitchcock Medical Center, Rocky Mountain Cancer Centers, Weill Cornell Medicine, The University of Kansas Cancer Center, Texas Oncology, Prisma Health, IHA Hematology Oncology Consultants, Mayo Clinic, Bristol-Myers Squibb (United States), Justus-Liebig-Universität Gießen, Willamette Valley Cancer Institute and Research Center
Language: English

Topic: Lymphoma Diagnosis and Treatment
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Keywords: lenalidomide, rituximab, follicular lymphoma, marginal zone lymphoma, induction therapy, maintenance therapy, overall response rate, progression-free survival
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W3211871624
Cites:
Cited by: 17
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security